图源:网络国外媒体称,2月24日,强生一纸诉状将三星Bioepis告上了美国新泽西州地区法院,原因是强生发现三星Bioepis与一家自有品牌供应商达成未经授权的分许可协议,强生认为这一行为严重违背了双方最初的约定。三星Bioepis是三星生物旗下开发生物类似药的企业,与强生产生利益争夺的,只有乌司奴单抗生物类似药PyzChiva。2023年11月,三星Bioepis与强生达成了专利诉讼和解,三星...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.